Emcor

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Emcor

Quick Facts

Property Description
Active ingredient Bisoprolol fumarate
Form Tablet / Film-coated tablet (Oral dosage form)
Pharmacological class Beta-adrenergic blocking agent (Beta-blocker)
General purpose Cardioprotection and Blood Pressure Modulation
Origin Synthetic compound

What Type of Medicine is Emcor?

Emcor is a prescription-only medicine whose active substance is Bisoprolol fumarate, a synthetic compound used for cardiovascular support. It is formally classified as a beta-adrenergic blocking agent, or beta-blocker. Specifically, Bisoprolol is noted for its high degree of cardioselective action, meaning its effect is preferentially exerted on the beta-1 receptors primarily situated within the heart tissue. This selectivity provides a focused therapeutic approach.

Composition and Pharmaceutical Form

The medicine is a single active ingredient product containing Bisoprolol fumarate, a recognized therapeutic agent. Emcor is prepared as a solid oral dosage form, typically a tablet or a film-coated tablet, which allows for the oral route of administration. As a specific formulation of Bisoprolol, its design facilitates consistent delivery of the active substance for foundational, long-term therapeutic application in adult patients.

General Purpose and Primary Benefit

The general purpose of Emcor is to provide sustained cardioprotective and antihypertensive support by moderating the heart’s function. Its selective action helps to reduce the impact of stress hormones on the heart, resulting in a controlled decrease in heart rate and lessening the force of contractions. This functional mechanism applies to the management of conditions that require long-term heart rhythm and pressure control, essential for maintaining cardiovascular stability.

Regulatory References

  1. WHO Essential Medicines List
  2. MedlinePlus Drug Information

What side effects are possible with Emcor?

Possible Side Effects and Safety Information

The officially documented adverse effects of Emcor (Bisoprolol fumarate) are organized by the system or organ affected (System-Organ Class) and the frequency observed in clinical use.

Frequency-Classified Adverse Reactions

  • Very Common (More than 1 in 10 patients): Bradycardia (slowed heart rate), specifically in patients being treated for chronic heart failure.
  • Common (1 to 10 in 100 patients): Fatigue, Dizziness, Headache, and Asthenia (weakness) often occur at the start of treatment. Common effects also include Gastrointestinal complaints (nausea, vomiting, diarrhea, constipation) and a sensation of coldness or numbness in the extremities.
  • Uncommon (1 to 10 in 1,000 patients): These include worsening of heart failure (especially early in therapy), sleep disorders, depression, bronchospasm (in susceptible patients with a history of airway disease), and muscle weakness.
  • Rare/Very Rare (Fewer than 1 in 1,000 patients): Syncope (fainting), Hepatitis (liver inflammation), elevated liver enzymes, reduced tear flow (relevant for contact lens users), and allergic skin reactions (e.g., pruritus, rash, alopecia) are listed as rare or very rare events.

High-Level Safety Considerations

The regulatory safety profile notes several important systemic and population-specific considerations. Serious adverse reactions include the potential for acute worsening of heart failure and severe cardiac conduction disturbances (atrioventricular block). The use of this medicine in patients with chronic heart failure has a formally documented high risk of bradycardia.

For patients with a history of obstructive airway disease, the risk of bronchospasm is an uncommon but specific safety concern. Additionally, the medicine may mask the typical warning signs of hypoglycemia (low blood sugar), such as a rapid heartbeat, in individuals with diabetes. The official labeling also documents that co-administration with other agents that depress cardiac function may substantially increase the risk of severe cardiac safety consequences, such as excessive hypotension.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define an overdose of Emcor (bisoprolol fumarate) as a potentially life-threatening event resulting from an excessive beta-adrenergic blocking effect. Any suspected or confirmed overdose mandates seeking immediate medical attention and contacting emergency services.

Documented Clinical Manifestations

An overdose is primarily recognized by signs of severe cardiodepression, which include profound hypotension (dangerously low blood pressure) and severe bradycardia (significantly slow heart rate). The official labeling also documents systemic manifestations, including acute cardiac failure, the risk of cardiogenic shock, bronchospasm, and hypoglycemia (low blood sugar).

Required Emergency Actions

Hospitalization is required for continuous monitoring and observation of vital signs until the patient's condition stabilizes. Management is strictly symptomatic and supportive, as no specific antidote is known for bisoprolol. Procedures to limit drug absorption, such as gastric lavage and the administration of activated charcoal, are officially described for immediate use following acute ingestion. Specific agents, including atropine, glucagon, and sympathomimetic agents, are listed in regulatory sources for managing the resulting severe clinical signs.

Therapeutic Uses of Emcor

What Emcor Treats: Main Uses and Benefits

This medication is commonly used for managing conditions characterized by periods of heightened symptoms. It is applied in situations involving certain distressing symptoms, including chronic stable angina pectoris, hypertension, and chronic stable heart failure.


Symptom Domains and Therapeutic Support

Emcor is used to help manage symptoms related to systemic imbalance, specifically the sustained force of elevated arterial pressure. By providing long-term support, it may assist with maintaining functional stability. It is also considered relevant for easing symptoms linked to functional stability becoming affected, such as those in chronic heart failure, providing support that helps ease the overall symptom burden, especially during phases when symptoms become more noticeable following events like a heart attack. Furthermore, it is commonly used to help manage exertional chest discomfort and may help patients cope more steadily with symptom fluctuations during physical activity.


Quick Fact: Support for Symptom Manifestations

Therapeutic Focus Symptom Category Addressed Patient Benefit
Chronic Stabilization Symptoms of increased physiological stress Assists with maintaining functional stability
Angina Prophylaxis Symptoms that become more disruptive during flare-ups Helps patients cope more steadily with symptom fluctuations

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who can and Cannot Use Emcor (Bisoprolol Fumarate) — Official Regulatory Information

Emcor (bisoprolol fumarate) is defined by official regulatory documents as having absolute contraindications based on specific cardiac, circulatory, and respiratory conditions.

Populations Who Must Not Use Emcor (Contraindications)

Use is strictly prohibited for patients experiencing:

  • Acute Heart Failure or decompensated heart failure requiring intravenous treatment.
  • Cardiogenic Shock.
  • Second or Third Degree AV Block (unless a pacemaker is present).
  • Marked Sinus Bradycardia (very slow heart rate) or Sick Sinus Syndrome.
  • Severe Bronchial Asthma or Severe Chronic Obstructive Pulmonary Disease (COPD).
  • Hypersensitivity to bisoprolol fumarate.

Populations Requiring Restricted or Conditional Use

  • Pediatric Population: Safety and effectiveness have not been established in children and adolescents; use is generally not recommended.
  • Severe Renal or Hepatic Impairment: Use requires caution and often lower maximum dosages due to slower clearance of the medicine.
  • Diabetes: Use requires caution as the medicine may mask symptoms of hypoglycemia, such as a rapid heartbeat.
  • Pregnancy and Lactation: Use during pregnancy is restricted to cases where the benefit justifies the risk to the fetus. Use during lactation is generally not recommended.
  • Abrupt Discontinuation: Stopping the medicine abruptly is contraindicated in patients with coronary artery disease and requires a gradual dose reduction.

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Emcor

Property Description
Medicinal product categories with documented interactions: Other beta-blocking agents, Calcium antagonists (Verapamil-, Diltiazem-, and Dihydropyridine-types), Class I antiarrhythmic drugs, Centrally-acting antihypertensives, Insulin and oral anti-diabetic agents, NSAIDs, Alcohol.
Specific interacting medicines (if explicitly listed): Rifampicin, Clonidine.
Mechanistic basis of interactions (only if stated in label): Increase of metabolic clearance (Pharmacokinetic), Negative influence on contractility (Pharmacodynamic), Reduction of hypotensive effect (Pharmacodynamic), Masking of hypoglycemia symptoms (Pharmacodynamic).
Timing-based interaction rules (if applicable): Bisoprolol must be discontinued for several days before the withdrawal of a centrally-acting antihypertensive to manage the risk of severe rebound hypertension.
Interaction-related restrictions: Co-administration with other beta-blocking agents (including topical) is contraindicated. The co-administration of intravenous Verapamil is prohibited.

Interaction Classifications (High-Level)

Classification Description
Interaction severity classification (as defined in official documents): Contraindicated combinations; Combinations generally not recommended (e.g., Verapamil-type/Class I antiarrhythmics); Combinations to be used with caution (e.g., Dihydropyridine CCBs/Rifampicin).
Regulatory basis (EMA / FDA / etc.): Information is based on government-issued Prescribing Information (FDA) and Summary of Product Characteristics (SmPC).

Official Interaction Statements

  • Co-administration with other beta-blocking agents is contraindicated due to the risk of additive systemic effects.
  • The use of Verapamil-type and Diltiazem-type calcium antagonists is generally not recommended due to negative effects on contractility and atrio-ventricular conduction.
  • Rifampicin increases the metabolic clearance of Bisoprolol, resulting in a shortened elimination half-life.
  • Bisoprolol may mask symptoms of hypoglycemia and increase the blood sugar lowering effect in patients taking Insulin or oral anti-diabetic agents.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce the hypotensive effect of Bisoprolol, a pharmacodynamic outcome.
  • Alcohol may have additive effects in lowering blood pressure.

Connection to the overall interaction profile

Regulatory documents establish the product's interaction structure primarily around pharmacodynamic reinforcement, cautioning against combinations that would increase negative inotropic or chronotropic effects. The profile also includes a specific pharmacokinetic interaction where increased metabolic clearance by Rifampicin is documented. Furthermore, the label defines mandatory procedural constraints concerning the timing of discontinuation for certain centrally-acting antihypertensives.

Mechanism of Action

Selective Blockade of Cardiac Beta Receptors

Emcor's active ingredient, Bisoprolol, acts as a highly specific competitive antagonist at the beta1-adrenergic receptors found predominantly on the heart's conduction system and myocardial tissue. By blocking the signal of stimulating hormones like epinephrine at this key target, the drug directly dampens the excitatory influence of the sympathetic nervous system on cardiac activity. This molecular action initiates an intracellular cascade that reduces the concentration of cyclic AMP (cAMP) and subsequent calcium release, leading to negative chronotropy (slowing the heart rate) and negative inotropy (reducing the force of contraction), consequentially decreases cardiac output and myocardial oxygen consumption.


Modulation of the Neurohormonal Axis

Beyond its direct effects on the heart, the drug's mechanism extends to regulating the Renin-Angiotensin System (RAS). It achieves this by blocking the same beta1-receptors located on the juxtaglomerular cells in the kidney, which are responsible for the secretion of the enzyme Renin. Suppressing Renin release is a foundational step that initiates modulation of the neurohormonal cascade responsible for regulating systemic blood vessel tone and resistance.

Dosage and Administration Information

How Emcor is Used: Official Administration Guidelines

Emcor (Bisoprolol fumarate) is administered through the oral route as a tablet and is generally prescribed for long-term therapy. Official instructions detail specific administration practices, dosing regimens, and procedural constraints that govern its use.


Administration Protocol

The medicine is taken once daily (OD), and is typically scheduled for the morning. The tablet must be swallowed whole with liquid and should not be crushed or chewed. Consumption may occur with or without food, as absorption is not dependent on meal timing.


Official Dosing Structure

The approved dosage ranges vary by the condition being addressed:

  • Hypertension and Angina Pectoris: Treatment usually begins at a starting dose of 5 mg once daily, with a typical maintenance dose of 10 mg. The daily dose is not to exceed 20 mg.
  • Chronic Stable Heart Failure: Treatment requires a highly controlled, gradual titration (dose increase) process, beginning at an initial dose of 1.25 mg once daily. The maintenance dose for this indication is typically 10 mg once daily as a maximum.

Special Procedural Requirements

Changes to the therapeutic course must be managed slowly. If treatment is to be discontinued, the dose must be gradually tapered over a period of days or weeks. For patients with severe renal or hepatic impairment, the maximum daily dose is generally restricted to 10 mg. If a dose is missed, it should be taken as soon as it is remembered, unless it is close to the next scheduled dose, in which case the missed dose should be skipped to prevent taking a double dose.

Recent Clinical Evidence

Emcor: Recent Clinical Evidence

This section summarizes the primary clinical research that has evaluated the active substance in Emcor, bisoprolol fumarate. This information is intended for educational background and should not be used as medical advice or a substitute for professional clinical judgment.


Core Research Focus

Bisoprolol fumarate, a highly beta1-selective adrenoceptor blocking agent, has been extensively studied, primarily through randomized controlled trials (RCTs). The principal applications evaluated in these clinical settings align with the drug's established uses:

  • Treatment of hypertension (high blood pressure).
  • Treatment of chronic stable angina pectoris (chest pain).
  • Treatment of stable chronic heart failure (CHF) with reduced left ventricular function.

Key Findings in Heart Failure Management

Research investigating the use of bisoprolol in stable chronic heart failure consistently included its administration in combination with other established medications, such as ACE inhibitors and diuretics. In these trials, the compound was studied to assess its influence on long-term outcomes and overall heart function in patient populations with reduced systolic left ventricular function (ejection fraction leq 35%, based on echocardiography).

Comparative Studies and Bioequivalence

Because bisoprolol is a well-established active substance, recent research often focuses on bioequivalence studies. These studies compare generic formulations of bisoprolol fumarate against the innovator product (Emcor) to demonstrate that differences in manufacturing methods or excipients do not lead to meaningful differences in drug absorption or overall effect. These comparisons are necessary to establish therapeutic equivalence and are not designed to test the efficacy of the active substance itself, which is already established through prior clinical investigation.

Key Studies & References Cardiac Insufficiency Bisoprolol Study III (CIBIS III): objectives and design

Frequently Asked Questions (FAQ)

Common questions about Emcor (FAQ)


Q: How quickly can a person typically expect to feel the effects of Emcor?

According to official product information, Emcor's active ingredient, bisoprolol, typically reaches its peak concentration in the blood within two to four hours after a dose is taken. This time frame indicates when the medicine is fully absorbed into the body.


Q: Does Emcor control blood pressure immediately, or does it take a few weeks?

While the drug's effects on the heart may begin within hours, regulatory studies indicate that the full blood pressure-lowering effect is often achieved within one week of starting the medicine. Clinical monitoring is typically performed to determine when the desired long-term control is established.


Q: Is Emcor a cure for high blood pressure or other heart conditions?

No. Official documents define Emcor as a treatment for high blood pressure and chronic heart failure. The medicine is used for the long-term management of these conditions to help control symptoms and support heart function, but it is not considered a cure.


Q: What are the known interactions between Emcor and common cold or cough medicines?

Official labeling notes that some cold and cough medicines contain sympathomimetic agents, such as decongestants, that can potentially raise blood pressure. Taking these agents with Emcor may counteract the medicine's intended blood pressure-lowering effect. It is important to review all over-the-counter medicines with a healthcare provider.


Q: What is the risk of having a bad reaction if I have many allergies?

Emcor is contraindicated (must not be used) if a person has a known hypersensitivity to bisoprolol. Furthermore, official information indicates that using a medicine like Emcor may lead to a heightened reaction if you encounter an allergen, and it may be more difficult to treat a severe allergic reaction with epinephrine. Persistent discomfort should be discussed with a healthcare provider.


Q: What are the most common side effects of Emcor that people experience?

The most common side effects documented include a slow heart rate (bradycardia), which is very common, especially in people with heart failure. Other common side effects are fatigue, dizziness, headache, coldness or numbness in the hands and feet, and gastrointestinal complaints (such as nausea or constipation).


Q: Is it normal to feel very tired or fatigued when first starting Emcor?

Yes. Regulatory labeling lists fatigue and general weakness (asthenia) as Common side effects. These effects are often noted to occur at the start of treatment, suggesting they may lessen over time as the body adjusts to the medicine.


Q: Does Emcor cause or contribute to weight gain?

Weight gain is not specifically listed as a common side effect in the official prescribing information for Emcor. However, for a person with heart failure, a sudden, rapid gain in weight may be a symptom of worsening heart failure and should be promptly reported to a healthcare provider.


Q: Can Emcor affect my sleep, such as causing insomnia or vivid dreams?

The official product documentation lists sleep disorders as an Uncommon side effect. This classification means that this side effect is reported in a relatively small percentage of patients.


Q: Is a slow heart rate a normal effect of Emcor, and when is it too slow?

A slow heart rate (bradycardia) is a Very Common and expected effect of the medicine. The label strictly contraindicates use in cases of marked sinus bradycardia (an excessively slow heart rhythm). Dizziness or fainting associated with a slow heart rate may be a sign that the rate is clinically too slow and requires medical review.


Q: Can Emcor cause cold hands and feet, and what can I do about it?

A sensation of coldness or numbness in the extremities (hands and feet) is listed as a Common side effect. Official patient-facing information typically does not provide management instructions for this effect. Any persistent discomfort should be discussed with a healthcare provider.


Q: Does taking Emcor affect my ability to drive or operate machinery?

Official prescribing information advises caution, stating that Emcor may cause dizziness or fatigue. These effects can affect the ability to drive or operate machinery. It is advised to use caution until a person knows how their body reacts to the medicine.


Q: Can Emcor cause or worsen feelings of anxiety or depression?

Depression is listed as an Uncommon side effect in the medicine's regulatory information. Anxiety or restlessness is also sometimes reported as a nervous system side effect.


Q: Does Emcor have a known impact on sexual health or libido?

Sexual dysfunction (impotence) is listed as an Uncommon side effect in the regulatory safety profile of Emcor.


Q: Does Emcor affect how my body reacts to epinephrine?

Yes. Regulatory documents state that Emcor may cause a reduced response to epinephrine (adrenaline), a medicine used to treat severe allergic reactions or shock. Higher doses of epinephrine may be required to achieve the desired effect in a patient taking Emcor.


Q: How does Emcor affect exercise performance?

Emcor works by slowing the heart rate and reducing the force of heart contractions. This action may prevent the heart rate from rising to the usual maximal levels during vigorous physical activity. If there are concerns about physical activity, these should be discussed with a healthcare provider.


Q: Can Emcor affect my vision or cause blurred sight?

Reduced tear flow (which may be relevant for contact lens users) is listed as a Rare/Very Rare effect. Blurred vision or eye irritation is also sometimes reported as an uncommon adverse reaction in official safety documents.


Q: Is the tiredness from Emcor a temporary side effect?

Regulatory safety information lists fatigue as a common side effect that often occurs at the start of treatment. This phrasing suggests the symptom may be temporary and could lessen as the body adjusts to the medicine.


Q: Can Emcor interact with other heart-related medications like calcium channel blockers?

Yes. Official documents list interactions with certain calcium antagonists (channel blockers), such as the Verapamil, Diltiazem, and Dihydropyridine types. These combinations are listed as generally not advised or requiring close supervision due to the risk of additive negative effects on heart function and conduction.

How should Emcor be stored and disposed of?

Storage and Disposal of Emcor Tablets

The storage of Emcor (Bisoprolol Fumarate) tablets must strictly follow official regulatory requirements to maintain product stability and safety.

Storage Requirements

Storage Component Requirement
Temperature Store at a temperature not above 30 C or below 25 C (depending on the specific formulation).
Protection Keep the medicine in the original package to protect it from light and moisture. The container must be kept tightly closed.
Safety The product must be stored out of the sight and reach of children.

Disposal Instructions

Official labeling mandates that unused or expired Emcor tablets must not be disposed of via household waste or wastewater.

Disposal must be conducted in accordance with local requirements. Patients should ask a pharmacist how to throw away medicines no longer used to ensure proper environmental protection.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Emcor found in:

A-Z Index: